Home » Stocks » Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc. (VRCA)

Stock Price: $10.30 USD 0.14 (1.38%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 265.89M
Revenue (ttm) n/a
Net Income (ttm) -30.55M
Shares Out 25.81M
EPS (ttm) -1.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $10.30
Previous Close $10.16
Change ($) 0.14
Change (%) 1.38%
Day's Open 10.41
Day's Range 10.07 - 10.72
Day's Volume 111,091
52-Week Range 6.79 - 18.67

More Stats

Market Cap 265.89M
Enterprise Value 212.10M
Earnings Date (est) Aug 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 25.81M
Float 8.29M
EPS (basic) -1.21
EPS (diluted) -1.23
FCF / Share -1.19
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 520,098
Short Ratio 10.87
Short % of Float 4.22%
Beta 2.38
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.90
Revenue n/a
Operating Income -31.93M
Net Income -30.55M
Free Cash Flow -29.78M
Net Cash 53.79M
Net Cash / Share 2.08
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -22.13%
ROE -43.84%
ROIC -49.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$21.33*
(107.09% upside)
Low
17.0
Current: 10.30
High
35.0
Target: 21.33
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue----
Operating Income-30.08-21.88-4.46-1.91
Net Income-28.21-20.65-4.46-1.91
Shares Outstanding24.9014.662.856.32
Earnings Per Share-1.13-1.41-1.56-0.30
Operating Cash Flow-27.41-17.87-4.58-1.61
Capital Expenditures-0.68-0.77--
Free Cash Flow-28.09-18.65-4.58-1.61
Cash & Equivalents62.0290.318.660.53
Total Debt0.19---
Net Cash / Debt61.8390.318.660.53
Assets68.4291.919.080.54
Liabilities3.412.480.620.42
Book Value65.0289.43-7.04-2.66
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Verrica Pharmaceuticals Inc.
Country United States
Employees 17
CEO Ted White

Stock Information

Ticker Symbol VRCA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VRCA
IPO Date June 15, 2018

Description

Verrica Pharmaceuticals Inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. It is also developing cantharidin-based product candidate, VP-103 for the treatment of plantar warts. The company was founded in 2013 and is headquartered in West Chester, Pennsylvania.